Table 2.
Top ten enrichment pathway analysis * of the Saudi CRC samples.
| Enrichment by Pathway Maps | Total | p-Value | FDR ** | In Data | Network Objects from Active Data |
|---|---|---|---|---|---|
| PI3K/AKT pathway | 50 | 1.303 × 10−18 | 1.521 × 10−15 | 17 | BAD, NF-kB p52/p65, JAK1, NF-kB p50/p65, c-Raf-1, NF-kB p65/c-Rel, RelA (p65 NF-kB subunit), PI3K reg class IA (p85-alpha), Pyk2(FAK2), PKC-alpha, PDK (PDPK1), NF-kB, c-Src, NF-kB1 (p105), PI3K reg class IA (p85), CDK2, FAK1 |
| Inhibition of Ephrin receptors in colorectal cancer | 30 | 7.103 × 10−18 | 4.144 × 10−15 | 14 | Ephrin-B receptors, Ephrin-A receptors, Ephrin-A receptor 2, Ephrin-B receptor 3, c-Rel (NF-kB subunit), Ephrin-B receptor 4, Ephrin-B receptor 2, Ephrin-A receptor 1, Beta-catenin, Ephrin-A receptor 3, Ephrin-B receptor 1, Ephrin-A receptor 7, Paxillin, FAK1 |
| Development of growth factors in regulation of oligodendrocyte progenitor cell proliferation | 67 | 1.477 × 10−17 | 5.747 × 10−15 | 18 | EGFR, KV1.6, c-Raf-1, IGF-1 receptor, PDK (PDPK1), HGF receptor (Met), FGFR1, ErbB2, Vitronectin, FGFR3, PKC, PDGF-R-alpha, PI3K reg class IA (p85), Fyn, Lyn, PLC-gamma 1, PI3K reg class IA, TrkA |
| Oxidative stress ROS-mediated MAPK activation via canonical pathways | 60 | 4.446 × 10−17 | 1.297 × 10−14 | 17 | EGFR, ERK5 (MAPK7), CaMK II, JNK(MAPK8-10), c-Raf-1, JNK2(MAPK9), Pyk2(FAK2), CaMK II alpha, FGFR1, JAK2, SFK, CaMK II delta, c-Src, PDGF-R-beta, Fyn, PLC-gamma 1, JNK1(MAPK8) |
| Immune response M-CSF-receptor signaling pathway | 81 | 5.906 × 10−16 | 1.378 × 10−13 | 18 | YES, ERK5 (MAPK7), CaMK II, JAK1, c-Raf-1, M-CSF receptor, Hck, c-Cbl, Pyk2(FAK2), PDK (PDPK1), Beta-catenin, NF-kB, PLC-gamma, PKC, c-Src, PI3K reg class IA (p85), Fyn, p120GAP |
| Development EGFR signaling pathway | 71 | 1.017 × 10−15 | 1.978 × 10−13 | 17 | EGFR, JAK1, c-Raf-1, c-Cbl, JNK2(MAPK9), PKC-alpha, PDK (PDPK1), NF-kB, PKC-beta, JAK2, ErbB2, c-Src, PI3K reg class IA (p85), PLC-gamma 1, FAK1, JNK1(MAPK8), p120GAP |
| Development VEGF signaling via VEGFR2—generic cascades | 93 | 7.941 × 10−15 | 1.323 × 10−12 | 18 | NF-kB p50/p65, c-Raf-1, VEGFR-2, CREB1, Pyk2(FAK2), PKC-alpha, PDK (PDPK1), Beta-catenin, PKC-beta, Paxillin, PKC, c-Src, eNOS, Fyn, PLC-gamma 1, PI3K reg class IA, FAK1, p120GAP |
| Proliferative action of Gastrin in gastric cancer | 53 | 8.453 × 10−14 | 1.233 × 10−11 | 14 | EGFR, c-Raf-1, CREB1, PKC-alpha, PDK (PDPK1), Beta-catenin, PKC-beta, JAK2, PKC, c-Src, PI3K reg class IA (p85), cPKC (conventional), PLC-gamma 1, FAK1 |
| Development: The role of GDNF ligand family/RET receptor in cell survival, growth, and proliferation | 92 | 1.026 × 10−13 | 1.330 × 10−11 | 17 | c-Raf-1, JNK2(MAPK9), CREB1, RET, CaMK II alpha, PDK (PDPK1), ATF-1, NF-kB, CREM (activators), Paxillin, VEGFR-1, c-Src, PI3K reg class IA (p85), PLC-gamma 1, CDK2, FAK1, JNK1(MAPK8) |
| Immune response IL-4 signaling pathway | 94 | 1.490 × 10−13 | 1.738 × 10−11 | 17 | BAD, JNK(MAPK8-10), GSK3 alpha/beta, JAK1, NF-kB p50/p65, c-Raf-1, c-Cbl, c-Rel (NF-kB subunit), CREB1, NF-kB p50/RelB, PI3K reg class IA (p85-alpha), PDK (PDPK1), PLC-gamma, JAK2, c-Fes, PKC, PLC-gamma 1 |
* Supplementary material S1: Enrichment pathway analysis, ** FDR: False discovery rate.